Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MATCH

Financiado

Cerrado

Discovering a novel allergen immunotherapy in house dust mite allergy tolerance...

Discovering a novel allergen immunotherapy in house dust mite allergy tolerance research The advances in medical sciences and biopharmaceutical development during the last decennia have been overwhelming. While the scientific and clinical insight in numerous diseases have significantly increased, the curative treatmen... ver más

30/06/2021

STICHTING AMSTERDA...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

STICHTING AMSTERDAM UMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-06-30

ERC-2019-POC: ERC Proof of Concept Grant

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

STICHTING AMSTERDAM UMC

150.00K€ | Lider

MORTEROS Y REVOCOS BIKAIN

250.77K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

AllergyVAX Next generation allergen immunotherapy based on specifically... 4M€ Cerrado

MAGIC Magnification of Asthma by human memory Group 2 Innate lymph... 178K€ Cerrado

RYC-2011-08734 Identification of novel targets on human dendritic cells to... 184K€ Cerrado

SAF2012-35670 DIFERENCIACION Y ESPECIALIZACION FUNCIONAL DE LAS CELULAS DE... 333K€ Cerrado

ALLFUN Fungi in the setting of inflammation allergy and autoimmune... 7M€ Cerrado

DC IN ASTHMA The impact of asthma on dendritic cell development analysis... 170K€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2019-12-19
Fecha Fin: 2021-06-30

Líder del proyecto

STICHTING AMSTERDAM UMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The advances in medical sciences and biopharmaceutical development during the last decennia have been overwhelming. While the scientific and clinical insight in numerous diseases have significantly increased, the curative treatment to most diseases is still not in reach. The most common diseases such as cancer and chronic diseases are still challenging scientists. Therefore, during our ERC Advanced project the main goal was to develop a vaccine to cure cancer using targeted immunotherapy. We used dendritic cells (DCs) as potentiator to improve anti-tumor T cell activity. However, we discovered that many tumors display a high content of sialic acids which actively suppress DCs function and induce tolerance to tumor associated antigens. This unexpected serendipity finding that sialylation of tumor associated antigens induced tolerance to the body’s immune response opens a window of opportunity to use sialylation (modification with sialic acid) to induce tolerance in allergies, such as house dust mite allergy (HDM). In the ERC PoC project (MATCH) I will couple HDM major allergens to specific sialic acid using a linker molecule to induce immune tolerance towards effector T cells in inflammation processes during HDM allergy. The results will lead to validation of the technology developed during the ERC Advanced project and PoC that sialylation induces tolerance when used with HDM allergens. When PoC is reached, the MATCH technology will represent a new allergen immunotherapy in a vaccine technology for HDM allergy with shorter treatment protocols, better efficacy and reduced side effects can be developed. The future potential of this technology may be extended to other allergies and/or autoimmune diseases.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores